OST-122 ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
97Ulcerative colitis2

97. Ulcerative colitis


Clinical trials : 2,630 Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04353791
(ClinicalTrials.gov)
September 16, 202024/3/2020Study of OST-122 in Patients With Moderate to Severe Ulcerative ColitisA Phase Ib/IIa, Randomized, Double Blind, Placebo Controlled, Multicenter Clinical Trial to Evaluate the Safety, Pharmacokinetics and Efficacy of Oral Treatment With OST-122 in Patients With Moderate to Severe Ulcerative ColitisUlcerative Colitis Chronic Moderate;Ulcerative Colitis Chronic SevereDrug: OST-122;Drug: PlaceboOncostellae S.LNULLCompleted18 Years75 YearsAll32Phase 1/Phase 2Spain;Ukraine
2EUCTR2019-004090-50-ES
(EUCTR)
07/02/202011/11/2019Clinical Trial to evaluate the safety and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitisA Phase Ib/IIa, randomized, double blind, placebo controlled, multicenter clinical trial to evaluate the safety, pharmacokinetics and efficacy of oral treatment with OST-122 in patients with moderate to severe ulcerative colitis Moderate to severe ulcerative colitis;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]Product Name: OST-122
INN or Proposed INN: Not available yet
Other descriptive name: OST-122
Product Name: OST-122
INN or Proposed INN: Not available yet
Other descriptive name: OST-122
ONCOSTELLAE S.L.NULLAuthorised-recruitment may be ongoing or finishedFemale: yes
Male: yes
32Phase 1;Phase 2Spain